<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nocturia: Clinical presentation, evaluation, and management in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nocturia: Clinical presentation, evaluation, and management in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nocturia: Clinical presentation, evaluation, and management in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Theodore M Johnson II, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael P O'Leary, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic will discuss the clinical presentation, evaluation, and treatment of nocturia in adults. Detailed discussions of some conditions that cause or are associated with nocturia are presented separately. (See  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a> and  <a class="medical medical_review" href="/z/d/html/6889.html" rel="external">"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia"</a> and  <a class="medical medical_review" href="/z/d/html/6874.html" rel="external">"Female urinary incontinence: Evaluation"</a>.)</p><p class="headingAnchor" id="H2228638726"><span class="h1">DEFINITION/DIAGNOSIS</span><span class="headingEndMark"> — </span>Nocturia is a common symptom rather than a disease and is defined as waking at night to void, where each micturition is preceded and followed by sleep [<a href="#rid1">1</a>]. Nocturia is likely clinically meaningful if a patient voids two or more times nightly [<a href="#rid2">2</a>]. The diagnosis is based on patient history.</p><p>New-onset adult nocturnal urinary incontinence or nighttime bed-wetting (enuresis) is distinct from nocturia and likely requires a different approach focusing on sleep problems or urinary obstruction [<a href="#rid3">3,4</a>]. In adults with no daytime symptoms or past history of pediatric bed-wetting enuresis, consideration should be given to causes of nocturnal syncope, including seizures or arrhythmia [<a href="#rid5">5,6</a>]. Urinary incontinence is discussed elsewhere. </p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>The prevalence of nocturia increases with increasing age [<a href="#rid7">7</a>]. Among 18- to 49-year-olds, more women than men have nocturia; the sex ratio reverses after 60 years of age, with greater prevalence in men than women [<a href="#rid8">8</a>]. Approximately 50 percent of adults between the ages of 50 to 79 have nocturia. Symptoms are occasional among those aged 50 to 59 years, and estimated as at least twice nightly among men between 70 and 79 [<a href="#rid8">8</a>].</p><p>Most studies indicate that the prevalence of nocturia is higher among Black and Hispanic adults, and that these differences are likely due to socioeconomic factors [<a href="#rid9">9-13</a>].</p><p>Many, but not all women with nocturia also have other urinary tract symptoms (eg, overactive bladder syndrome or polyuria) [<a href="#rid7">7,12,14</a>]. While pregnant women commonly have nocturia, it nearly always resolves by three months postpartum [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/404.html" rel="external">"Maternal adaptations to pregnancy: Renal and urinary tract physiology"</a>.)</p><p>Most epidemiological studies of nocturia are cross-sectional, which makes separating causes, effects, and markers for risk of nocturia difficult. Potentially modifiable conditions that likely cause nocturia include obesity, uncontrolled hypertension, poorly controlled diabetes, restless leg syndrome and periodic limb movements, obstructive sleep apnea (OSA), gastroesophageal reflux [<a href="#rid16">16</a>], benign prostatic hyperplasia (BPH), and congestive heart failure [<a href="#rid17">17-21</a>]. Longitudinal studies have shown that the temporal relationship between depression and nocturia appears to be bidirectional, with prevalent nocturia associated with a higher risk of incident depression and vice versa [<a href="#rid22">22,23</a>].</p><p class="headingAnchor" id="H3714215259"><span class="h1">CLINICAL SIGNIFICANCE</span><span class="headingEndMark"> — </span>Nocturia is a source of significant bother for some patients, especially if there are two or more episodes per night [<a href="#rid24">24,25</a>]. It is one of the most distressing symptoms in older men with benign prostatic hyperplasia (BPH) [<a href="#rid26">26</a>] and is strongly associated with poor quality-of-life ratings [<a href="#rid27">27</a>]. Patients report nocturia as a leading cause of sleep disturbance, affecting both sleep onset and maintenance [<a href="#rid28">28</a>]. Difficulty returning to sleep and morning fatigue contribute to the negative impact [<a href="#rid29">29</a>].</p><p>Nocturia is associated with increased rates of depression [<a href="#rid17">17</a>], work absenteeism [<a href="#rid30">30</a>], and lower self-rated physical and mental health [<a href="#rid18">18</a>]. In older patients, it is associated with higher rates of accidental falls [<a href="#rid31">31-33</a>] and subsequent fractures [<a href="#rid34">34,35</a>].</p><p class="headingAnchor" id="H4"><span class="h1">PATHOPHYSIOLOGY AND ASSOCIATED CONDITIONS</span><span class="headingEndMark"> — </span>Nocturia can be attributed to any disorder or condition  (<a class="graphic graphic_table graphicRef67664" href="/z/d/graphic/67664.html" rel="external">table 1</a>) that causes one of the following [<a href="#rid36">36,37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Low-volume bladder voiding</p><p class="bulletIndent1"><span class="glyph">●</span>Increased volume of nighttime urinary output</p><p class="bulletIndent1"><span class="glyph">●</span>Sleep disturbance</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Low-volume bladder voids</span><span class="headingEndMark"> — </span>Low-volume voids may be due to either reduced bladder capacity or impaired bladder function. The two most common causes of low-volume bladder voids are an overactive bladder and bladder outlet obstruction, often related to benign prostatic hypertrophy (BPH). Reduced bladder volume is common in older patients, likely due to age-related changes in the bladder or detrusor hyperactivity [<a href="#rid38">38,39</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Increased nighttime urinary volume</span><span class="headingEndMark"> — </span>An increase in urinary volume at night may be due to a higher percentage of the total daily urine output being excreted at night (nocturnal polyuria) or an increase in the total 24-hour urine output (polyuria).</p><p class="headingAnchor" id="H7"><span class="h3">Nocturnal polyuria</span><span class="headingEndMark"> — </span>The normal physiologic pattern of urination is a decrease in nighttime, relative to daytime, urine output. Overproduction of urine at night, with a normal 24-hour urine output, is called nocturnal polyuria [<a href="#rid40">40</a>]. It is defined as a urine volume during sleep greater than 33 percent of the 24-hour urine volume [<a href="#rid41">41</a>]. Causes include:</p><p class="bulletIndent1"><span class="glyph">●</span>Decrease in arginine vasopressin – There is a normal diurnal periodicity in arginine vasopressin (AVP), with higher AVP plasma levels in the evening leading to decreased nighttime urine output [<a href="#rid42">42</a>]. However, this diurnal variation is absent in many older subjects and likely contributes to age-related increases in nocturia. [<a href="#rid43">43,44</a>]</p><p></p><p class="bulletIndent1">There are also age-related changes in the action of AVP [<a href="#rid45">45,46</a>]. AVP, a peptide hormone secreted by the neurohypophyseal system, is released when plasma osmolality is increased or blood pressure has decreased (as seen with orthostasis, vasodilation, or significant blood loss). AVP targets receptors in the renal distal tubules to increase urine concentration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure or other edematous states (nephrotic syndrome and venous insufficiency) cause interstitial edema. Assumption of the supine position permits mobilization of some of the edema fluid into the vascular space and leads to a solute diuresis.</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Polyuria</span><span class="headingEndMark"> — </span>Global polyuria is defined as a 24-hour urine volume that exceeds 3 liters per day (or 40 mL per kg) and is mainly caused by a water diuresis. Solute-induced polyuria is rare and mainly seen in the inpatient setting following a high-solute load (eg, enteral or parental feedings) or following relief of urinary obstruction [<a href="#rid47">47</a>]. Causes of polyuria seen in the outpatient setting include uncontrolled diabetes mellitus, arginine vasopressin disorders, and primary polydipsia. (See  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Sleep disorders</span><span class="headingEndMark"> — </span>Nocturia is the most frequently cited cause of poor sleep quality and insomnia in older adults, and it is a common feature in patients with obstructive sleep apnea (OSA) [<a href="#rid48">48-51</a>].</p><p>OSA may cause nocturnal polyuria by release of atrial natriuretic peptide (ANP) due to negative intrathoracic pressure and stretching of the myocardium [<a href="#rid52">52</a>]. ANP release causes vasodilation and inhibits aldosterone, resulting in increased sodium and water excretion. Continuous positive airway pressure can result in significant reductions in ANP levels, nighttime urine volume, and in nocturia episodes in patients with OSA [<a href="#rid53">53-56</a>].</p><p>In addition, patients with other primary sleep problems (restless leg syndrome, and periodic limb movements at night) may awaken due to sleep disturbance but recall this as an awakening to void [<a href="#rid57">57</a>]. Some nocturia treatment strategies target sleep disturbance directly. (See <a class="local">'Sleep disorder medications'</a> below.)</p><p class="headingAnchor" id="H931012712"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Patients may initiate a discussion of their sleep being interrupted by nighttime voiding, or the clinician might learn of nocturia during a review of symptoms. Symptoms are usually gradual in onset and have variable night-to-night occurrence.</p><p>Occasionally, nocturia can be an indicator of worsening of an underlying disease, such as chronic kidney disease [<a href="#rid58">58</a>], <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> toxicity [<a href="#rid59">59</a>], diabetes mellitus, or congestive heart failure.</p><p class="headingAnchor" id="H12"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Patients with nocturia should have a targeted evaluation  (<a class="graphic graphic_table graphicRef82467" href="/z/d/graphic/82467.html" rel="external">table 2</a>) [<a href="#rid60">60</a>]. It is more valuable to quantify and understand how much distress nocturia causes the patient than to focus on obtaining a precise count of nightly episodes [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H13"><span class="h2">History</span><span class="headingEndMark"> — </span>Elements of the history include nocturia symptoms, fluid intake patterns, medications, comorbid conditions, dry mouth, and urinary tract symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nocturia symptoms</strong> – Examples of informative questions include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>How often do you get up at night to void?</p><p class="bulletIndent2"><span class="glyph">•</span>How much does waking at night to void bother you?</p><p class="bulletIndent2"><span class="glyph">•</span>Are you afraid of falling, do you feel dizzy, or have you fallen when you get up?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid intake</strong> – Very large fluid intake (&gt;40 mL/kg per day) may be responsible for nocturia. Follow-up questions about the reason for the large fluid intake (psychogenic, history of renal stones, vigorous outdoor exercise, general health belief about fluid intake, attempt at weight loss, arginine vasopressin disorders) are important in developing a meaningful treatment plan.</p><p></p><p class="bulletIndent1">Some patients may drink large volumes immediately prior to bedtime. Although clinicians should make a recommendation to reduce nighttime fluid intake, patients will often have initiated this on their own prior to seeking help. Intake of diuretic fluids such as caffeine or alcohol should be asked about.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sodium intake</strong> – Inquire about sodium intake and consider reviewing a dietary history. Counsel on reducing intake of dietary items with high sodium intake [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Certain prescription and over-the-counter medications (eg, diuretics, xanthines, beta blockers, cholinesterase inhibitors) may be related to nocturia onset or worsening.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbid conditions</strong> – Relevant, addressable conditions include congestive heart failure, diabetes mellitus, peripheral edema, depression, and nighttime pain [<a href="#rid19">19,64</a>]. Nocturia may improve with treatment of one of these conditions if it is a direct and principal cause [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sleep dysfunction</strong> – Obstructive sleep apnea (OSA) should be considered as a possible diagnosis in patients with nocturia, and the close association between the conditions has led to a suggestion that nocturia should be a screening question for OSA [<a href="#rid66">66</a>]. Insomnia (difficulty returning to sleep) and daytime sleepiness contribute to increased bother from nocturia [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinary tract symptoms</strong> – These include obstructive symptoms (hesitancy, weak stream, incomplete emptying, or intermittency), irritative symptoms (urinary frequency, urgency), and urinary incontinence.</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>We perform the following elements of the physical examination:</p><p class="bulletIndent1"><span class="glyph">●</span>Measure orthostatic vital signs in all patients due to the risk of nocturnal falls, and in men with benign prostatic hyperplasia (BPH) due to the consideration of prescribing alpha-1-adrenergic antagonists.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate for volume overload suggestive of congestive heart failure or nephrotic syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palpate the lower abdomen to evaluate for bladder distention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perform a rectal examination to detect fecal impaction, evaluate resting and volitional rectal tone (which may be important for teaching pelvic floor muscle exercise-based strategies), and estimate gross prostate size in men.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inspect for peripheral edema [<a href="#rid67">67</a>].</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Frequency-volume chart</span><span class="headingEndMark"> — </span>Although patients may find it difficult to perform properly, a 24-hour recording of void time and void amount (using a collection device), along with times of going to bed and awakenings, can be helpful in identifying the causes of nocturia. We find this a useful tool in initial diagnosis, but it can also be used in patients who do not respond to initial management [<a href="#rid68">68</a>]. Results can help determine whether nocturia is due to low-volume voiding, increased nocturnal polyuria, or both [<a href="#rid69">69</a>]. For example, documentation of a low functional bladder capacity (the largest bladder volume void in 24 hours) may suggest that low-volume voiding is the problem. By contrast, a normal functional bladder capacity during the day but low volume voids at night may suggest a primary sleep disorder. Results can highlight the presence of high-volume urine output, either just at night (nocturnal polyuria) or over the entire day. A sample log is provided  (<a class="graphic graphic_form graphicRef64573" href="/z/d/graphic/64573.html" rel="external">form 1</a>).</p><p>In interpreting the frequency voiding diary, nocturia episodes are voids that occur between going to bed and rising in the morning; the first morning void should not be counted as a nocturia episode (unless the individual was intending to sleep longer but could not return to sleep and remained awake) [<a href="#rid70">70</a>]. A determination of nocturnal polyuria can be made if the nighttime urine volume (including the first morning void) is greater than 35 percent of the 24-hour urine volume [<a href="#rid40">40</a>]. If the voiding record shows that the 24-hour urine output is higher than expected, it is important to confirm fluid intake. A log of the patient's complete fluid intake (including daytime) may be helpful [<a href="#rid70">70</a>]. </p><p class="headingAnchor" id="H20"><span class="h2">Clinical testing</span><span class="headingEndMark"> — </span>Measurement of urinary peak flow rate is not necessary. Post-void residual (PVR) measurement is used selectively.</p><p>PVR testing by catheterization or ultrasound can be helpful in diagnosing bladder outlet obstruction or urinary retention. Certain physical examination findings increase the suspicion for urinary retention, including abdominal fullness, suprapubic tenderness, or a patient’s strong urge to void during suprapubic palpation or percussion. Urinary retention may also be suspected in patients with neurologic conditions affecting the bladder such as diabetic neuropathy, older men with prominent symptoms of intermittent or low flow with voiding, and those with a history of genitourinary surgery. If PVR testing is to be performed, ultrasound testing is preferred to a catheterization because of reduced chance of infection and greater patient comfort.</p><p>An elevated PVR (greater than 200 mL) should limit the use of a bladder relaxant medication as these patients are at increased risk of urinary retention (beyond the baseline risk of 1 in 200 treated patients) [<a href="#rid71">71</a>]. In general, a PVR of less than 50 mL is considered adequate emptying, and a PVR greater than 200 mL requires further evaluation, which might include a medication review for discontinuation of any anticholinergic medications, or initial treatment with an alpha-blocker [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>We measure renal function, electrolytes, and serum glucose and obtain a urinalysis in all patients, with urine culture if an infection is suspected.</p><p>Urine cytology or cystoscopy are indicated only if hematuria or pelvic pain is present. (See  <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">"Etiology and evaluation of hematuria in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5467.html" rel="external">"Chronic pelvic pain in adult females: Evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/6880.html" rel="external">"Chronic prostatitis and chronic pelvic pain syndrome"</a>.)</p><p>Patients with undiagnosed prostate cancer are usually asymptomatic. Nonetheless, prostate-specific antigen (PSA) testing may be reasonable in the evaluation of men with nocturia and other lower urinary symptoms. (See  <a class="medical medical_review" href="/z/d/html/6889.html" rel="external">"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The goals of nocturia treatment are to decrease the bother of symptoms and to reduce the number of nocturia episodes, as complete resolution of nocturia is probably unrealistic [<a href="#rid73">73</a>]. Because nocturia can be a manifestation of various conditions, numerous treatments are potentially helpful, and multicomponent interventions are recommended [<a href="#rid74">74-76</a>]. Patients without an underlying medical condition who are not bothered by nocturia do not need treatment. Most treatments show only a small reduction in episodes of nocturia when compared with placebo, ranging from 0 to 0.8 fewer episodes per night.</p><p class="headingAnchor" id="H2228259703"><span class="h2">Treatment of underlying medical conditions</span><span class="headingEndMark"> — </span>Medical conditions which may cause or contribute to nocturia should be treated as part of initial management. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Polydipsia – Psychogenic (&gt;10L per day) or other</p><p class="bulletIndent1"><span class="glyph">●</span>Congestive heart failure or peripheral edema</p><p class="bulletIndent1"><span class="glyph">●</span>Poorly controlled diabetes mellitus</p><p class="bulletIndent1"><span class="glyph">●</span>Gastroesophageal reflux disease (GERD) or nighttime cough</p><p class="bulletIndent1"><span class="glyph">●</span>Sleep disorders such as obstructive sleep apnea (OSA), periodic limb movements/restless leg syndrome, and insomnia [<a href="#rid77">77</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Obesity – Discuss weight optimization as part of healthy lifestyle advice [<a href="#rid78">78</a>]; in morbid obesity treated with surgery, nocturia may diminish [<a href="#rid79">79</a>]</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Initial measures</span><span class="headingEndMark"> — </span>There are several intervention strategies that should be considered in all patients  (<a class="graphic graphic_algorithm graphicRef121548" href="/z/d/graphic/121548.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Decreasing nocturnal urine output</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduction of overall fluid intake, especially if it is excessive, and specific reduction of evening intake by taking in this fluid earlier in the afternoon [<a href="#rid80">80</a>]. Care should be taken not to restrict fluid intake in older patients who have borderline or inadequate fluid intake to meet daily needs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduction of salt intake [<a href="#rid81">81,82</a>], particularly for those with congestive heart failure [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduction of evening consumption of diuretic fluids, including caffeine and alcohol.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoiding use of nighttime diuretics. Clinicians may direct patients on twice-daily diuretics to move the nighttime dose to the mid-afternoon.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of peripheral edema by use of compression stockings or afternoon elevation of the legs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoidance of nocturnal hyperglycemia in patients with diabetes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Double-voiding prior to bedtime, which can be described as urinating while sitting comfortably on the toilet (men included), leaning slightly forward, and then waiting for 20 to 30 seconds to urinate again, may be helpful in individuals who feel that they have not completely emptied their bladder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreasing the impact of nocturia – The use of a handheld urinal or a bedside commode may be helpful for patients bothered by trips to and from the bathroom at night. Nighttime ambulation may be particularly worrisome or hazardous in older adult patients or others at high risk of falling, so attention to environmental safety (eg, clear pathway, motion-activated floor way lighting) is also important.</p><p></p><p class="bulletIndent1">In addition, adopting good sleep hygiene can reduce episodes of nighttime voiding. Elements include sleeping in a quiet room with low lighting and appropriate temperature, avoiding nighttime use of electronic devices, and avoiding daytime naps.</p><p></p><p class="headingAnchor" id="H538792070"><span class="h2">Behavioral treatment, including pelvic floor muscle exercises</span><span class="headingEndMark"> — </span>Pelvic floor muscle exercises (PFME, or Kegel exercises) and urge-suppression strategies (a combination of remaining still and not running to the bathroom, use of relaxation strategies with three to five rapid contractions of the pelvic floor muscles) are useful in females and males with nocturia [<a href="#rid60">60,83-87</a>]. PFME strengthen the muscular components of the urethral closure mechanism using principles of strength training: small numbers of isometric repetitions at maximal exertion.</p><p>The patient’s ability to perform these exercise can be tested on rectal examination and will not usually require the use of computer-assisted biofeedback [<a href="#rid87">87,88</a>]. Primary care providers should refer patients to physical therapists who specialize in this training. The basic recommended regimen is three sets of 8 to 12 slow-velocity contractions sustained for six to eight seconds each, performed three or four times a week and continued for at least 15 to 20 weeks [<a href="#rid89">89</a>].</p><p>In clinical trials, benefits from this therapy can be seen as early as two to four weeks, with full benefit at 10 to 12 weeks [<a href="#rid88">88</a>]. Reduction in nocturia from these interventions has ranged from 0.5 to 1.4 episodes per night [<a href="#rid85">85,88</a>] and in pilot studies has shown improvements in sleep quality, reduced bother from nocturia, and improvement in nocturia symptom-specific quality-of-life metrics [<a href="#rid88">88</a>]. (See  <a class="medical medical_patient" href="/z/d/html/8403.html" rel="external">"Patient education: Pelvic floor muscle exercises (Beyond the Basics)"</a>.)</p><p>Simultaneous behavioral treatment of nocturia and insomnia will likely be effective in reducing nocturia and bother from nocturia [<a href="#rid90">90,91</a>]. </p><p class="headingAnchor" id="H355478937"><span class="h2">Approach to pharmacologic therapy</span><span class="headingEndMark"> — </span>We offer pharmacologic therapy to patients who continue to have symptoms after initial measures. Initial therapy is based on sex, and, in men, on whether or not benign prostatic hyperplasia (BPH) is present. However, single-agent pharmacologic treatments for nocturia are limited in their effectiveness and are less effective than multicomponent interventions  (<a class="graphic graphic_algorithm graphicRef122285" href="/z/d/graphic/122285.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H25"><span class="h3">Men with benign prostatic hyperplasia</span></p><p class="headingAnchor" id="H26"><span class="h4">Initial monotherapy: alpha-1-adrenergic antagonists</span><span class="headingEndMark"> — </span>We start therapy with alpha-1-adrenergic antagonists. These agents target the dynamic component of bladder outlet obstruction and can reduce several BPH symptoms, including nocturia. The presence of dizziness, low blood pressure, or orthostasis may be contraindications. Symptom reduction, if it occurs, can be expected within a month.</p><p>Reductions in nocturia with alpha-1-adrenergic antagonists are modest (on average net 0.2 to 0.4 fewer episodes versus placebo) and less than the response to other BPH-related symptoms [<a href="#rid92">92</a>]. In one secondary data analysis of a randomized trial, nocturia reduction of 50 percent or greater occurred in 39 percent of men treated with <a class="drug drug_general" data-topicid="9975" href="/z/d/drug information/9975.html" rel="external">terazosin</a>, compared with 22 percent of men treated with placebo [<a href="#rid92">92</a>]. This relatively small effect in research trials with populations selected to have the best chance for benefit and carefully monitored for compliance [<a href="#rid93">93,94</a>] suggests that nocturia response in the general population will likely be even more minimal.</p><p><a class="drug drug_general" data-topicid="9975" href="/z/d/drug information/9975.html" rel="external">Terazosin</a> and <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">doxazosin</a> are often associated with dizziness and orthostatic hypotension, which may be of particular concern in patients with nocturia. These side effects can be minimized with gradual dose titration. <a class="drug drug_general" data-topicid="9654" href="/z/d/drug information/9654.html" rel="external">Tamsulosin</a> and <a class="drug drug_general" data-topicid="9105" href="/z/d/drug information/9105.html" rel="external">alfuzosin</a> do not require dose titration, and initial starting doses are usually well-tolerated with an incidence of dizziness and orthostasis of 1 to 2 percent [<a href="#rid95">95,96</a>]. Higher doses may result in higher frequency of side effects. (See  <a class="medical medical_review" href="/z/d/html/6891.html" rel="external">"Medical treatment of benign prostatic hyperplasia"</a>.)</p><p class="headingAnchor" id="H2362704460"><span class="h4">Combination therapy</span><span class="headingEndMark"> — </span>We suggest combination therapy for patients who continue to have symptoms on an alpha-1-adrenergic antagonist. Most patients can be offered combination therapy with either PFME or with a bladder relaxant [<a href="#rid97">97</a>]. Contraindications to and side effects of bladder relaxant medications limit their usefulness. (See <a class="local">'Initial monotherapy: bladder relaxant therapies'</a> below.)</p><p>For men over age 70 who have continued symptoms on an alpha-1-adrenergic antagonist and who have a prostate larger than 35 g or a prostate-specific antigen (PSA) greater than 1.5, we consider adding a 5-alpha reductase inhibitor. These agents decrease nocturia by reducing the size of the prostate gland. Treatment for four to six months is generally needed before prostate size is sufficiently reduced to improve symptoms. (See  <a class="medical medical_review" href="/z/d/html/6891.html" rel="external">"Medical treatment of benign prostatic hyperplasia"</a>.)</p><p>However, the efficacy of long-term therapy with 5-alpha reductase inhibitors is limited [<a href="#rid93">93</a>]. The Medical Therapy of Prostatic Symptoms (MTOPS) trial demonstrated benefit with <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> on a combined endpoint of reduction of BPH symptoms, need for intervention for urinary retention, and reduction of urinary symptoms. Combination therapy (finasteride plus <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">doxazosin</a>) was superior to therapy with either single agent. However, the net benefit of combination therapy compared with placebo, with respect to nocturia, was small, with a difference of less than 0.2 fewer nightly episodes at one- and four-year follow-up [<a href="#rid98">98</a>].</p><p class="headingAnchor" id="H2696258213"><span class="h4">Role of surgery</span><span class="headingEndMark"> — </span>Prostatectomy for BPH relieves many symptoms, but nocturia is the symptom that persists most frequently following surgery [<a href="#rid99">99</a>]. Some have suggested that BPH is often mistakenly implicated as the cause of nocturia in men [<a href="#rid100">100</a>]. Overall, surgical options are not recommended as first-line treatment for bothersome nocturia. However, for properly selected patients with severe, persistent prostatic symptoms in addition to nocturia, there may be reduction in nocturia that results from prostatic tissue removal when there is bladder outlet obstruction [<a href="#rid101">101</a>]. More details on this topic can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8093.html" rel="external">"Surgical treatment of benign prostatic hyperplasia (BPH)"</a>.)</p><p class="headingAnchor" id="H2631970167"><span class="h3">Women, and men without benign prostatic hypertrophy</span></p><p class="headingAnchor" id="H28"><span class="h4">Initial monotherapy: bladder relaxant therapies</span><span class="headingEndMark"> — </span>We offer bladder relaxant therapies as first-line pharmacologic treatment. Bladder relaxant medications may reduce nocturia by increasing bladder capacity and decreasing urge-associated voids. Agents differ in drug class, efficacy, side effects, costs, and impact on comorbid conditions. However, the demonstrated benefit of bladder relaxants over placebo in nocturia reduction has been small [<a href="#rid85">85,102,103</a>], perhaps owing to the inability of these medications to increase nighttime voided volumes [<a href="#rid104">104</a>].</p><p>There are two major drug classes: antimuscarinics and beta-3 agonists. In general, the initial choice of agents is guided by side effects to avoid. Antimuscarinic agents and B-3 agonists can be combined, but there has been no demonstrated improvement in nocturia with combination therapy [<a href="#rid105">105</a>]. Antimuscarinic agents should be avoided in patients with cognitive dysfunction (eg, dementia, delirium, confusion), dry mouth, or severe constipation. Beta-3 agonists should be given with caution in patients with baseline tachycardia or poorly controlled hypertension. These agents are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/114501.html" rel="external">"Urgency urinary incontinence/overactive bladder (OAB) in females: Treatment", section on 'Medication prescribing details'</a>.)</p><p>There is concern that bladder relaxant therapies may predispose men to urinary retention. Although urodynamic studies have shown a small increase in the post-void residual (PVR) with use of <a class="drug drug_general" data-topicid="10292" href="/z/d/drug information/10292.html" rel="external">tolterodine</a> this small change has not proven to be clinically meaningful [<a href="#rid71">71,106</a>] and both tolterodine and <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">oxybutynin</a> have been used successfully, with clinical monitoring, in older male patients [<a href="#rid86">86,107</a>].</p><p class="headingAnchor" id="H707683163"><span class="h5">Antimuscarinic agents</span><span class="headingEndMark"> — </span>These agents have direct antispasmodic effects and inhibit the action of acetylcholine on smooth muscle. <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">Oxybutynin</a> is the most commonly used; other agents include <a class="drug drug_general" data-topicid="10292" href="/z/d/drug information/10292.html" rel="external">tolterodine</a> and <a class="drug drug_general" data-topicid="10313" href="/z/d/drug information/10313.html" rel="external">solifenacin</a>.</p><p>All antimuscarinic agents have anticholinergic effects which include dry mouth, constipation, blurred vision for near objects, tachycardia, drowsiness, and decreased cognitive function. These agents are contraindicated in patients with uncontrolled tachyarrhythmias, myasthenia gravis, gastric retention, and narrow angle-closure glaucoma and are discouraged in patients with cognitive impairment.</p><p>Additional concerns with antimuscarinic agents include increased risk of gastric ulceration in patients taking slow-release <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a> due to delayed gastric emptying [<a href="#rid108">108</a>] and increased risk of urinary retention in patients with severe BPH symptoms [<a href="#rid55">55</a>].</p><p><a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">Oxybutynin</a> is available in immediate release (IR), extended release (ER), and transdermal formulations. We recommend the ER formulation as it has fewer side effects (particularly less dry mouth), and a better safety profile.</p><p>While most individuals benefit from <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">oxybutynin</a> 10 mg ER, some patients will still have benefit at a lower dose (5 mg ER), and rarely will patients require 20 or 30 mg ER [<a href="#rid86">86,87</a>]. The effect of antimuscarinic agents on nocturia are small with reduction of nocturia by approximately 0.30 episodes per night compared with placebo (no reduction) [<a href="#rid85">85,87,102,109,110</a>].</p><p class="headingAnchor" id="H1929075583"><span class="h5">Beta-3 agonists</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="85675" href="/z/d/drug information/85675.html" rel="external">Mirabegron</a> and <a class="drug drug_general" data-topicid="130397" href="/z/d/drug information/130397.html" rel="external">vibegron</a> [<a href="#rid111">111,112</a>], beta 3-adrenoceptor agonists, are an option for patients who have a contraindication to antimuscarinic medications. These agents work by promoting selective beta receptor stimulation of the detrusor muscle to enhance smooth muscle relaxation. Mirabegron has similar efficacy to antimuscarinics [<a href="#rid113">113</a>]. Hypertension is the most common side effect with mirabegron; additional side effects are mostly secondary to elevated blood pressures. Mirabegron and vibegron has been shown to reduce nocturia by a modest degree [<a href="#rid114">114,115</a>]. Patients with severe or uncontrolled hypertension should not be prescribed a drug in this class [<a href="#rid113">113</a>].</p><p class="headingAnchor" id="H629458395"><span class="h5">Vaginal estrogen therapy (women only)</span><span class="headingEndMark"> — </span>For postmenopausal women, it is reasonable to use topical vaginal estrogen therapy either alone or in combination with other therapies  (<a class="graphic graphic_table graphicRef58506" href="/z/d/graphic/58506.html" rel="external">table 3</a>).</p><p>A systematic review of randomized and observational studies evaluating topical estrogen for the treatment of nocturia in postmenopausal women reported that three of the five studies (60 percent) that reported this outcome reported a reduction in frequency of nocturia compared with placebo [<a href="#rid116">116</a>]. There did not appear to be a difference in efficacy or safety among the different preparations (vaginal tablets, ovules, creams, gels, or rings). (See  <a class="medical medical_review" href="/z/d/html/6881.html" rel="external">"Female urinary incontinence: Treatment", section on 'Topical vaginal estrogen'</a>.)</p><p class="headingAnchor" id="H1609079617"><span class="h3">Refractory nocturia</span><span class="headingEndMark"> — </span>For patients who do not achieve a satisfactory response to therapies described above, there are alternative treatments to be considered based on patient eligibility and clinical indication.</p><p class="headingAnchor" id="H1714235050"><span class="h4">Desmopressin</span><span class="headingEndMark"> — </span>In 2018, the US Food and Drug Administration (FDA) approved two lower-potency [<a href="#rid117">117</a>] <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> analogs, of which one is still available (a sublingual pastille [Nocdurna]), for treatment of nocturia due to nocturnal polyuria [<a href="#rid118">118,119</a>]. However, United States insurance companies have asked for patients to be tried on a higher-potency (generic) formulation(s) of desmopressin acetate prior to receiving approval for the sublingual pastille [<a href="#rid120">120</a>].</p><p>While there are data showing the efficacy of <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a>, there is a substantial risk of hyponatremia, which can be life-threatening if severe, that limits its use. Specifically, it has been demonstrated to cause hyponatremia at a 13-fold higher rate than other medications for lower urinary tract symptoms [<a href="#rid121">121</a>]. In particular, older adults with nocturia have a high prevalence of medical conditions, concomitant medications, and baseline laboratory abnormalities that likely increase the risk of potentially severe adverse side effects from desmopressin [<a href="#rid122">122</a>]. Since roughly three-quarters of those over 80 years of age with nocturia have a contraindication to these agents, a careful evaluation should be performed. Given the potential for harm from treatment of a condition related to quality of life, a shared decision-making process when considering this therapy is appropriate. If used, monitoring of sodium is necessary prior to initiation, once within the first week, once at 30 days, and periodically during therapy due to the potential of severe hyponatremia [<a href="#rid117">117</a>]. (See <a class="local">'Monitoring'</a> below and <a class="local">'Safety'</a> below.)</p><p><a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">Desmopressin</a> is a neuropeptide similar to endogenous vasopressin; like vasopressin, it has a potent antidiuretic effect, but unlike vasopressin it has no vasopressor activity [<a href="#rid123">123</a>]. desmopressin, taken two hours prior to bedtime, reduces nighttime free-water excretion to provide an opportunity for adequate sleep free from voiding; however, the safety of its use depends on compensatory daytime free-water diuresis, which helps to prevent hyponatremia. Hyponatremia should be considered a dose-related adverse drug reaction likely resulting from reduced drug clearance in certain patients [<a href="#rid124">124</a>]. For some individuals, desmopressin has a narrow therapeutic window and it may be difficult to achieve an effective dose that does not cause hyponatremia. This may be due to either increased bioavailability or reduced excretion.</p><p>Daytime polyuria and frequency resulting from <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> use may be bothersome to some patients.</p><p class="headingAnchor" id="H3544377768"><span class="h5">Contraindications</span></p><p class="bulletIndent1"><span class="glyph">●</span>The principal contraindications to <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> related to the increased risk of hyponatremia are described in the Nocdurna package insert [<a href="#rid118">118</a>] and include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyponatremia (&lt;135 mEq/L) at baseline, syndrome of inappropriate antidiuretic hormone secretion (SIADH), or a history of hyponatremia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of loop diuretics.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A history of congestive heart failure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of systemic or inhaled glucocorticoids. However, an expert consensus panel did not feel that inhaled glucocorticoids were an absolute contraindication [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polydipsia, such as psychogenic polydipsia (a fluid intake of ≥10 liters per day).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use during an illnesses that can cause fluid or electrolyte imbalances (eg, gastroenteritis, salt-wasting nephropathies, systemic infection).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diminished renal function (estimated glomerular filtration rate [eGFR] of ≤49.9 mL/min/1.73 m<sup>2</sup>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An expert consensus panel felt that use of thiazide diuretics should be considered an absolute contraindication [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An expert consensus panel felt that <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> should not be used in frail older adults [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent1">The author avoids the use of <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> in patients aged ≥65 years due to the high likelihood that older adults with nocturia are highly likely to have contraindications to use and because the manufacturers as well as an expert consensus panel have failed to provide clear instructions for the frequency of needed monitoring [<a href="#rid117">117</a>]. Older adults will have a higher incidence of hyponatremia and higher likelihood of concurrent use of other medications that may depress serum sodium levels in this age group [<a href="#rid125">125-128</a>] (see <a class="local">'Monitoring'</a> below). Desmopressin is rated as a potentially inappropriate medication according to the Beers criteria for medications for older adults. (See  <a class="medical medical_review" href="/z/d/html/3013.html" rel="external">"Drug prescribing for older adults", section on 'Beers criteria'</a>.)</p><p></p><p class="bulletIndent1">Patients taking certain medications are at increased risk for hyponatremia. Although not an absolute contraindication to use, more frequent monitoring of serum sodium is indicated. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">Desmopressin</a> should be avoided in patients who have:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An underlying disease that would be made worse by fluid retention (eg, uncontrolled hypertension, increased intracranial pressure)</p><p class="bulletIndent2"><span class="glyph">•</span>A history of urinary retention</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The nasal preparation should not be given to patients who have nasal conditions that may increase absorption (eg, atrophy of nasal mucosa, acute or chronic rhinitis).</p><p></p><p>Individuals taking <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> who develop a contraindication to therapy should have the medication stopped and a subsequent reevaluation for appropriateness of the drug after resolution of the condition.</p><p class="headingAnchor" id="H2415573999"><span class="h5">Formulations</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">Desmopressin</a> is available in several formulations: as a sublingual tablet/pastille (Nocdurna), a generic intranasal preparation (desmopressin acetate), and an oral tablet (off-label). There are no comparative trials among these formulations, and the side effect profiles appear to be similar.</p><p>All formulations of <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> are associated with hyponatremia. Nocdurna was both approved with a boxed warning regarding hyponatremia stating that these medications are recognized to “cause hyponatremia” and that “severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death.” While older, generic formulations of desmopressin carry the same, or higher, risk for hyponatremia, these agents do not have a black box warning [<a href="#rid129">129</a>]. However, sublingual pastilles and nasal spray preparations have the advantage over the oral tablet of not requiring gastric absorption which can be variable, and thus have more predictable drug levels by avoiding first pass metabolism. Some patients cannot use nasal sprays due to nasal congestion or difficulty regulating the number of nasal sprays used.</p><p>Formulations include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sublingual tablet</strong> – Nocdurna is an orally disintegrating sublingual tablet of <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> acetate available as 27.7 mcg tablets (equivalent to 25 mcg of desmopressin) and 55.3 mcg tablets (equivalent to 50 mcg of desmopressin), with the 27.7 mcg dosage recommended in women due to their higher risk of hyponatremia. In two studies, the minimal effective dose for women was equivalent to 25 mcg [<a href="#rid125">125,126</a>]. One study showed a minimal effective dose for men equivalent to 100 mcg, whereas the other found 50 mcg to also be efficacious. The dosages recommended by the manufacturer are 27.7 mcg for women and 55.3 mcg for men, in both cases taken without water one hour prior to bedtime. Hyponatremia was more prevalent at higher doses, in older individuals, and in women [<a href="#rid126">126</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intranasal</strong> – There is a generic formulation <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> nasal spray that has not been approved by the FDA for treatment of nocturia. It is available as 10 mcg per spray and a dosage range of 10 to 40 mcg per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral tablet </strong>– <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">Desmopressin</a> is also available as an oral tablet with a shorter half-life. Previously, it had been the most commonly used formulation for treatment of nocturia, although this use is off-label [<a href="#rid130">130</a>]. Absorption from the gastrointestinal tract can be variable and is limited (about 5 percent); therefore, the oral drug has about one-tenth to one-twentieth the potency of the nasal form. Oral desmopressin is available in 0.1, 0.2, and 0.4 mg doses. The initial oral dose for nocturia is 0.1 mg, although some experts suggest a 0.05 mg starting dose. Oral desmopressin should not be taken with meals, in order to maximize absorption, and should be started at the lowest possible dose [<a href="#rid131">131-133</a>].</p><p></p><p class="headingAnchor" id="H3139442808"><span class="h5">Efficacy</span><span class="headingEndMark"> — </span>These agents have demonstrated efficacy over placebo in trials. However, their effect has not reached the threshold of minimally important clinical difference, which is likely around a 1.5 to 2.2 reduction in voids per night.</p><p>In a 2017 systematic review of 14 randomized trials in men with nocturia, <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> (oral, sublingual and intranasal formulations) was associated with a reduction in the number of nocturnal voids over 3 to 12 months compared with placebo (mean difference [MD] -0.85, 95% CI -1.17 to -0.53), with one major adverse event [<a href="#rid134">134</a>]. However, there was no benefit of desmopressin in short-term evaluation (up to three months) and no benefit in the combined use of desmopressin with an alpha-1-adrenergic antagonist or anticholinergic drug. Minimal benefit was found in clinical trials of intranasal desmopressin. Among individuals ≥age 50 years with a baseline of 3.3 episodes of nocturia per night, desmopressin nasal spray decreased episodes to 1.9 per night compared with 2.1 episodes on placebo [<a href="#rid135">135</a>].</p><p>Oral <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> is effective in treating adults with nocturia. A 2014 systematic review of 10 placebo-controlled randomized trials found that desmopressin doses of ≥0.025 mg decreased nocturnal voids and increased time to first void [<a href="#rid133">133</a>]. A dose of 0.1 mg provided one additional hour of sleep before the first void and 0.72 fewer voids per night. The absolute risk increase of hyponatremia was 5.1 percent.</p><p class="headingAnchor" id="H3767855430"><span class="h5">Safety</span><span class="headingEndMark"> — </span>The risk of hyponatremia in patients on <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> is of considerable concern; therefore, patients at increased risk for hyponatremia should not take this medication. (See <a class="local">'Contraindications'</a> above.)</p><p>The mechanism for hyponatremia is that some individuals on <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> therapy do not have a free-water daytime excretion. Rather, they continue to excrete a concentrated, hyperosmolar urine well into the day, which induces hyponatremia. While mild hyponatremia may present with a headache [<a href="#rid133">133</a>] or be asymptomatic, severe hyponatremia may result in seizures or be life-threatening [<a href="#rid136">136</a>]. Severe hyponatremia has occurred even within the higher frequency of monitoring performed in clinical trials where structured monitoring and lower-dose initiation of desmopressin has been performed [<a href="#rid132">132</a>].</p><p>The frequency of reported hyponatremia with <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> ranges from 3 to 30 percent, with a pooled estimate of 7.6 percent (95% CI 3.7-15.1) [<a href="#rid137">137</a>]. In patients using intranasal formulations, clinically significant hyponatremia (126 to 129 mEq/L ) was reported in 2.2 percent of those who received desmopressin and none who received placebo, and severe hyponatremia (≤125 mEq/L ) was reported in 0.7 percent of those on desmopressin compared with 0.3 percent on placebo. All of the patients who had severe hyponatremia were older than 65 years [<a href="#rid135">135</a>]. Newer formulations of desmopressin, such as the oral disintegrating tablet, offer lower concentrations of active medication, but their use may still result in clinically significant or severe hyponatremia, particularly when given at higher than the minimally effective dose or when given to women and those over 65 years of age [<a href="#rid138">138</a>]. Symptoms of hyponatremia can be worrisome and myriad (nausea and vomiting, headache, confusion, loss of energy, drowsiness and fatigue, restlessness and irritability, muscle weakness, spasms or cramps, seizures, and coma) [<a href="#rid117">117</a>]. Individuals who develop these symptoms should stop desmopressin pending results of a serum sodium check. </p><p class="headingAnchor" id="H563914695"><span class="h5">Monitoring</span><span class="headingEndMark"> — </span>Serum sodium levels should be monitored and the medication discontinued if the sodium falls below 135 mEq/L (equivalent to 135 mmol/L). While the majority of individuals who will develop hyponatremia do so in the first month of treatment, hyponatremia can also occur later [<a href="#rid138">138</a>].</p><p>Serum sodium levels should be obtained prior to therapy, within one week of initiating therapy, one month after therapy is initiated, and periodically thereafter during treatment.</p><p>There are inadequate data upon which to base the optimum frequency of periodic monitoring. The author suggests monitoring every six months for patients at average risk of hyponatremia and every three months for those at increased risk of hyponatremia (eg, those over the age of 65, or patients taking certain concomitant medications including nonsteroidal antiinflammatory drugs [NSAIDs], selective serotonin reuptake inhibitors [SSRIs], tricyclic antidepressants [TCAs], thiazide diuretics, opioids, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, or <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>). Treatment should be discontinued in patients who cannot comply with monitoring.</p><p>In addition, all patients should have serum sodium monitored within three to seven days after each dose change <strong>and</strong> with any change in patient status, such as fluid retention, headaches, confusion, and/or disorientation.</p><p>Patients should also be monitored for the development of contraindications to therapy or a new medication that interacts with <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a>.</p><p class="headingAnchor" id="H106920308"><span class="h4">Posterior tibial nerve stimulation</span><span class="headingEndMark"> — </span>Posterior tibial nerve stimulation (PTNS) treatment involves 12 weekly 30-minute sessions of transcutaneous needle nerve stimulation near the ankle, approximating pudendal nerve stimulation. PTNS has been studied in a sham-controlled randomized trial of 214 patients with overactive bladder [<a href="#rid139">139</a>]. The number of nocturia episodes in the group assigned to weekly PTNS for 12 weeks decreased compared with sham control (a decrease of 0.7 versus 0.3 episodes from a baseline of 2.9 nightly episodes). Improvement in nocturia was sustained over a 12-month period (0.8 episodes less than baseline) when participants had additional treatment on an average of every two to three weeks. It is not known if these gains would be maintained without ongoing treatment [<a href="#rid140">140</a>]. In a treatment trial in 76 women, PTNS and transcutaneous tibial nerve stimulation (TTNS) added to bladder training reduced bother from nocturia versus bladder training alone (1.84, 1.90, and 0.47 episodes reduction for each group, respectively) [<a href="#rid141">141</a>].</p><p class="headingAnchor" id="H35"><span class="h4">Sleep disorder medications</span><span class="headingEndMark"> — </span>Sleep medications can provide a decrease in nocturia episodes. One randomized study investigated melatonin as a potential treatment for nocturia associated with bladder outlet obstruction in older men [<a href="#rid142">142</a>]. Baseline frequency of nocturia was 3.1 episodes per night. Melatonin showed a nonsignificant reduction in nocturia compared with placebo (-.3 and -0.05 episodes respectively) and significantly reduced reported bother.</p><p class="headingAnchor" id="H36"><span class="h4">Afternoon diuretic therapy</span><span class="headingEndMark"> — </span>Several small studies have evaluated the effectiveness of an afternoon diuretic dose specific prescribed for nocturia. In two randomized trials, nocturia was reduced by approximately 0.5 episodes per night [<a href="#rid143">143,144</a>]. Combining antidiuretic therapy (at bedtime) with diuretic therapy (six hours prior to bedtime) increased the effect size of reduction of nocturia but was accompanied by hyponatremia in several cases [<a href="#rid145">145</a>].</p><p class="headingAnchor" id="H38"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and goals of management</strong> – Nocturia is a symptom, defined as any waking at night to void, most often considered clinically significant if a patient voids two or more times nightly. It is important to try to reduce the bother caused by the nocturia in addition to reducing nocturia episodes. (See <a class="local">'Definition/Diagnosis'</a> above and <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recognition of underlying causes</strong> – Nocturia may be caused by conditions or disorders that result in low bladder volume voids, nocturnal polyuria, or sleep disturbances. Certain medical conditions may contribute to nocturia and should be treated as part of initial management. Many patients have multiple etiologies. (See <a class="local">'Pathophysiology and associated conditions'</a> above and <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Evaluation for nocturia should focus on patterns of fluid intake, other urinary symptoms, symptoms of possible underlying causes, and a focused physical examination. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A frequency-volume chart (ie, a voiding diary) will be helpful in determining the contributing causes of nocturia. Nocturnal polyuria is defined as the excretion of ≥35 percent of the 24-hour urine output during the hours of sleep  (<a class="graphic graphic_form graphicRef64573" href="/z/d/graphic/64573.html" rel="external">form 1</a>). (See <a class="local">'Frequency-volume chart'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong> – Initial measures should include adjustments in timing of fluid intake to earlier in the day, reducing salt intake if excessive, and eliminating nighttime diuretic use if present. A urinal or commode near the bed may be helpful. Fall risk at night should be considered  (<a class="graphic graphic_algorithm graphicRef121548" href="/z/d/graphic/121548.html" rel="external">algorithm 1</a>). (See <a class="local">'Initial measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pelvic floor muscle exercises</strong> – We suggest pelvic floor exercises for all patients (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Primary care providers should refer patients to physical therapists who specialize in this training. (See <a class="local">'Behavioral treatment, including pelvic floor muscle exercises'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic treatment</strong> – Suggested initial treatment trials for nocturia include the following  (<a class="graphic graphic_algorithm graphicRef122285" href="/z/d/graphic/122285.html" rel="external">algorithm 2</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In men with nocturia related to benign prostatic hyperplasia (BPH), we suggest trials of alpha-1-adrenergic antagonists with or without 5-alpha reductase inhibitors (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Men with benign prostatic hyperplasia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients without BPH who have low-volume voids, we suggest trials of bladder muscle relaxants (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial monotherapy: bladder relaxant therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For postmenopausal women with continued nocturia despite a bladder muscle relaxant, we offer topical vaginal estrogen either alone or in combination with other therapies. (See <a class="local">'Vaginal estrogen therapy (women only)'</a> above.)</p><p></p><p class="bulletIndent1">Because each of these therapies is associated with only a modest reduction in the number of nighttime voids and also has potential for side effects, many patients may choose no pharmacologic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory nocturia</strong> – For patients with refractory nocturia and who are &lt;65 years of age, we consider treatment with <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a>. Studies suggest that desmopressin has a small effect on nighttime voiding frequency that is of uncertain clinical significance. Baseline sodium levels must be normal, and patients must be able to recognize and report subtle fluid status changes and also be willing to undergo frequent monitoring of sodium levels in order to avoid severe hyponatremia. Desmopressin is a potentially inappropriate medication according to Beers criteria for medications for older adults. (See <a class="local">'Desmopressin'</a> above and  <a class="medical medical_review" href="/z/d/html/3013.html" rel="external">"Drug prescribing for older adults", section on 'Beers criteria'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010; 21:5.</a></li><li><a class="nounderline abstract_t">Tikkinen KA, Johnson TM 2nd, Tammela TL, et al. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol 2010; 57:488.</a></li><li><a class="nounderline abstract_t">Sakamoto K, Blaivas JG. Adult onset nocturnal enuresis. J Urol 2001; 165:1914.</a></li><li><a class="nounderline abstract_t">Kramer NR, Bonitati AE, Millman RP. Enuresis and obstructive sleep apnea in adults. Chest 1998; 114:634.</a></li><li><a class="nounderline abstract_t">Imamura H, Kamijo H, Nitta K, Okada A. Nocturnal enuresis as the initial symptom of life-threatening arrhythmia: a case report. BJGP Open 2018; 2:bjgpopen18X101624.</a></li><li><a class="nounderline abstract_t">Chorin E, Chorin O, Mann T, et al. Bedwetting from the heart: Time for a paradigm shift in the minimal diagnostic evaluation of enuresis. Heart Rhythm 2022; 19:862.</a></li><li><a class="nounderline abstract_t">Bosch JL, Weiss JP. The prevalence and causes of nocturia. J Urol 2013; 189:S86.</a></li><li><a class="nounderline abstract_t">Tikkinen KA, Tammela TL, Huhtala H, Auvinen A. Is nocturia equally common among men and women? A population based study in Finland. J Urol 2006; 175:596.</a></li><li><a class="nounderline abstract_t">Markland AD, Vaughan CP, Johnson TM 2nd, et al. Prevalence of nocturia in United States men: results from the National Health and Nutrition Examination Survey. J Urol 2011; 185:998.</a></li><li><a class="nounderline abstract_t">Kupelian V, Link CL, Hall SA, McKinlay JB. Are racial/ethnic disparities in the prevalence of nocturia due to socioeconomic status? Results of the BACH survey. J Urol 2009; 181:1756.</a></li><li><a class="nounderline abstract_t">Burgio KL, Johnson TM 2nd, Goode PS, et al. Prevalence and correlates of nocturia in community-dwelling older adults. J Am Geriatr Soc 2010; 58:861.</a></li><li><a class="nounderline abstract_t">Hsu A, Nakagawa S, Walter LC, et al. The burden of nocturia among middle-aged and older women. Obstet Gynecol 2015; 125:35.</a></li><li><a class="nounderline abstract_t">Dessie SG, Adams SR, Modest AM, et al. Bladder Symptoms and Attitudes in an Ethnically Diverse Population. Female Pelvic Med Reconstr Surg 2016; 22:37.</a></li><li><a class="nounderline abstract_t">Robinson D, Cardozo L. Overactive bladder: diagnosis and management. Maturitas 2012; 71:188.</a></li><li><a class="nounderline abstract_t">Viktrup L. The risk of lower urinary tract symptoms five years after the first delivery. Neurourol Urodyn 2002; 21:2.</a></li><li><a class="nounderline abstract_t">Tikkinen KA, Auvinen A, Tiitinen A, et al. Reproductive factors associated with nocturia and urinary urgency in women: a population-based study in Finland. Am J Obstet Gynecol 2008; 199:153.e1.</a></li><li><a class="nounderline abstract_t">van der Vaart CH, Roovers JP, de Leeuw JR, Heintz AP. Association between urogenital symptoms and depression in community-dwelling women aged 20 to 70 years. Urology 2007; 69:691.</a></li><li><a class="nounderline abstract_t">Fitzgerald MP, Litman HJ, Link CL, et al. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey. J Urol 2007; 177:1385.</a></li><li><a class="nounderline abstract_t">Johnson TM 2nd, Sattin RW, Parmelee P, et al. Evaluating potentially modifiable risk factors for prevalent and incident nocturia in older adults. J Am Geriatr Soc 2005; 53:1011.</a></li><li><a class="nounderline abstract_t">Tikkinen KA, Auvinen A, Johnson TM 2nd, et al. A systematic evaluation of factors associated with nocturia--the population-based FINNO study. Am J Epidemiol 2009; 170:361.</a></li><li><a class="nounderline abstract_t">Laven BA, Orsini N, Andersson SO, et al. Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol 2008; 179:1891.</a></li><li><a class="nounderline abstract_t">Obayashi K, Saeki K, Negoro H, Kurumatani N. Nocturia increases the incidence of depressive symptoms: a longitudinal study of the HEIJO-KYO cohort. BJU Int 2017; 120:280.</a></li><li><a class="nounderline abstract_t">Breyer BN, Shindel AW, Erickson BA, et al. The association of depression, anxiety and nocturia: a systematic review. J Urol 2013; 190:953.</a></li><li><a class="nounderline abstract_t">A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. The Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia. J Urol 1993; 150:1696.</a></li><li><a class="nounderline abstract_t">Chen FY, Dai YT, Liu CK, et al. Perception of nocturia and medical consulting behavior among community-dwelling women. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18:431.</a></li><li><a class="nounderline abstract_t">DuBeau CE, Yalla SV, Resnick NM. Implications of the most bothersome prostatism symptom for clinical care and outcomes research. J Am Geriatr Soc 1995; 43:985.</a></li><li><a class="nounderline abstract_t">Van Dijk MM, Wijkstra H, Debruyne FM, et al. The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int 2010; 105:1141.</a></li><li><a class="nounderline abstract_t">Middelkoop HA, Smilde-van den Doel DA, Neven AK, et al. Subjective sleep characteristics of 1,485 males and females aged 50-93: effects of sex and age, and factors related to self-evaluated quality of sleep. J Gerontol A Biol Sci Med Sci 1996; 51:M108.</a></li><li><a class="nounderline abstract_t">Vaughan CP, Eisenstein R, Bliwise DL, et al. Self-rated sleep characteristics and bother from nocturia. Int J Clin Pract 2012; 66:369.</a></li><li><a class="nounderline abstract_t">Asplund R, Henriksson S, Johansson S, Isacsson G. Nocturia and depression. BJU Int 2004; 93:1253.</a></li><li><a class="nounderline abstract_t">Vaughan CP, Brown CJ, Goode PS, et al. The association of nocturia with incident falls in an elderly community-dwelling cohort. Int J Clin Pract 2010; 64:577.</a></li><li><a class="nounderline abstract_t">Stewart RB, Moore MT, May FE, et al. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992; 40:1217.</a></li><li><a class="nounderline abstract_t">Galizia G, Langellotto A, Cacciatore F, et al. Association between nocturia and falls-related long-term mortality risk in the elderly. J Am Med Dir Assoc 2012; 13:640.</a></li><li><a class="nounderline abstract_t">Temml C, Ponholzer A, Gutjahr G, et al. Nocturia is an age-independent risk factor for hip-fractures in men. Neurourol Urodyn 2009; 28:949.</a></li><li><a class="nounderline abstract_t">Nakagawa H, Niu K, Hozawa A, et al. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol 2010; 184:1413.</a></li><li><a class="nounderline abstract_t">Weiss JP, Blaivas JG. Nocturia. J Urol 2000; 163:5.</a></li><li><a class="nounderline abstract_t">Marshall SD, Raskolnikov D, Blanker MH, et al. Nocturia: Current Levels of Evidence and Recommendations From the International Consultation on Male Lower Urinary Tract Symptoms. Urology 2015; 85:1291.</a></li><li><a class="nounderline abstract_t">van Haarst EP, Heldeweg EA, Newling DW, Schlatmann TJ. The 24-h frequency-volume chart in adults reporting no voiding complaints: defining reference values and analysing variables. BJU Int 2004; 93:1257.</a></li><li><a class="nounderline abstract_t">Pfisterer MH, Griffiths DJ, Schaefer W, Resnick NM. The effect of age on lower urinary tract function: a study in women. J Am Geriatr Soc 2006; 54:405.</a></li><li><a class="nounderline abstract_t">Weiss JP, Blaivas JG, Stember DS, Chaikin DC. Evaluation of the etiology of nocturia in men: the nocturia and nocturnal bladder capacity indices. Neurourol Urodyn 1999; 18:559.</a></li><li><a class="nounderline abstract_t">van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:179.</a></li><li><a class="nounderline abstract_t">George CP, Messerli FH, Genest J, et al. Diurnal variation of plasma vasopressin in man. J Clin Endocrinol Metab 1975; 41:332.</a></li><li><a class="nounderline abstract_t">Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med 1991; 229:131.</a></li><li><a class="nounderline abstract_t">Matthiesen TB, Rittig S, Nørgaard JP, et al. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol 1996; 156:1292.</a></li><li><a class="nounderline abstract_t">Miller M. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc 2000; 48:1321.</a></li><li><a class="nounderline abstract_t">Kirkland JL, Lye M, Levy DW, Banerjee AK. Patterns of urine flow and electrolyte excretion in healthy elderly people. Br Med J (Clin Res Ed) 1983; 287:1665.</a></li><li><a class="nounderline abstract_t">Bhasin B, Velez JC. Evaluation of Polyuria: The Roles of Solute Loading and Water Diuresis. Am J Kidney Dis 2016; 67:507.</a></li><li><a class="nounderline abstract_t">Bliwise DL, Foley DJ, Vitiello MV, et al. Nocturia and disturbed sleep in the elderly. Sleep Med 2009; 10:540.</a></li><li><a class="nounderline abstract_t">Hajduk IA, Strollo PJ Jr, Jasani RR, et al. Prevalence and predictors of nocturia in obstructive sleep apnea-hypopnea syndrome--a retrospective study. Sleep 2003; 26:61.</a></li><li><a class="nounderline abstract_t">Moriyama Y, Miwa K, Tanaka H, et al. Nocturia in men less than 50 years of age may be associated with obstructive sleep apnea syndrome. Urology 2008; 71:1096.</a></li><li><a class="nounderline abstract_t">Lowenstein L, Kenton K, Brubaker L, et al. The relationship between obstructive sleep apnea, nocturia, and daytime overactive bladder syndrome in women. Am J Obstet Gynecol 2008; 198:598.e1.</a></li><li><a class="nounderline abstract_t">Fitzgerald MP, Mulligan M, Parthasarathy S. Nocturic frequency is related to severity of obstructive sleep apnea, improves with continuous positive airways treatment. Am J Obstet Gynecol 2006; 194:1399.</a></li><li><a class="nounderline abstract_t">Margel D, Shochat T, Getzler O, et al. Continuous positive airway pressure reduces nocturia in patients with obstructive sleep apnea. Urology 2006; 67:974.</a></li><li><a class="nounderline abstract_t">Umlauf MG, Chasens ER, Greevy RA, et al. Obstructive sleep apnea, nocturia and polyuria in older adults. Sleep 2004; 27:139.</a></li><li><a class="nounderline abstract_t">Krieger J, Laks L, Wilcox I, et al. Atrial natriuretic peptide release during sleep in patients with obstructive sleep apnoea before and during treatment with nasal continuous positive airway pressure. Clin Sci (Lond) 1989; 77:407.</a></li><li><a class="nounderline abstract_t">Wang T, Huang W, Zong H, Zhang Y. The Efficacy of Continuous Positive Airway Pressure Therapy on Nocturia in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. Int Neurourol J 2015; 19:178.</a></li><li><a class="nounderline abstract_t">Pressman MR, Figueroa WG, Kendrick-Mohamed J, et al. Nocturia. A rarely recognized symptom of sleep apnea and other occult sleep disorders. Arch Intern Med 1996; 156:545.</a></li><li><a class="nounderline abstract_t">Hillier P, Knapp MS, Cove-Smith R. Circadian variations in urine excretion in chronic renal failure. Q J Med 1980; 49:461.</a></li><li><a class="nounderline abstract_t">Kinahan JC, NiChorcorain A, Cunningham S, et al. Diagnostic Accuracy of Tests for Polyuria in Lithium-Treated Patients. J Clin Psychopharmacol 2015; 35:434.</a></li><li><a class="nounderline abstract_t">Teunissen TA, de Jonge A, van Weel C, Lagro-Janssen AL. Treating urinary incontinence in the elderly--conservative therapies that work: a systematic review. J Fam Pract 2004; 53:25.</a></li><li><a class="nounderline abstract_t">Michel MC, Oelke M, Goepel M, et al. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. Neurourol Urodyn 2007; 26:190.</a></li><li><a class="nounderline abstract_t">Matsuo T, Miyata Y, Sakai H. Daily salt intake is an independent risk factor for pollakiuria and nocturia. Int J Urol 2017; 24:384.</a></li><li><a class="nounderline abstract_t">Monaghan TF, Michelson KP, Wu ZD, et al. Sodium restriction improves nocturia in patients at a cardiology clinic. J Clin Hypertens (Greenwich) 2020; 22:633.</a></li><li><a class="nounderline abstract_t">Niimi A, Suzuki M, Yamaguchi Y, et al. Sleep Apnea and Circadian Extracellular Fluid Change as Independent Factors for Nocturnal Polyuria. J Urol 2016; 196:1183.</a></li><li><a class="nounderline abstract_t">Smith M, Dawson S, Andrews RC, et al. Evaluation and Treatment in Urology for Nocturia Caused by Nonurological Mechanisms: Guidance from the PLANET Study. Eur Urol Focus 2022; 8:89.</a></li><li><a class="nounderline abstract_t">Romero E, Krakow B, Haynes P, Ulibarri V. Nocturia and snoring: predictive symptoms for obstructive sleep apnea. Sleep Breath 2010; 14:337.</a></li><li><a class="nounderline abstract_t">Hirayama A, Torimoto K, Yamada A, et al. Relationship between nocturnal urine volume, leg edema, and urinary antidiuretic hormone in older men. Urology 2011; 77:1426.</a></li><li><a class="nounderline abstract_t">Abrams P, Klevmark B. Frequency volume charts: an indispensable part of lower urinary tract assessment. Scand J Urol Nephrol Suppl 1996; 179:47.</a></li><li><a class="nounderline abstract_t">Weiss JP. Nocturia: "do the math". J Urol 2006; 175:S16.</a></li><li><a class="nounderline abstract_t">Ochoa DC, Hashim H. The Importance of Terminology for Quantifying Nocturia in Practice. Eur Urol Focus 2022; 8:81.</a></li><li><a class="nounderline abstract_t">Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174:2273.</a></li><li class="breakAll">Fantl JA, et al.. Urinary incontinence in adults: Acute and chronic management. Clinical Practice Guideline No. 2, 1996 Update. AHCPR Publication NO. 96-0682, Agency for Health Care Policy and Research; Department of Health and Human Services, Rockville, MD 1996.</li><li><a class="nounderline abstract_t">Weiss JP, Wein AJ, van Kerrebroeck P, et al. Nocturia: new directions. Neurourol Urodyn 2011; 30:700.</a></li><li class="breakAll">Fonda D, DuBeau CE, Hatari MD, et al. Incontinence in the frail elderly. In: Incontinence, Abrams P, Cardozo L, Khoury S, et al (Eds), Health Publications Ltd, Paris 2005.</li><li><a class="nounderline abstract_t">Soda T, Masui K, Okuno H, et al. Efficacy of nondrug lifestyle measures for the treatment of nocturia. J Urol 2010; 184:1000.</a></li><li><a class="nounderline abstract_t">Johnson TM, Endeshaw Y, Nagamia Z, et al. A multicomponent intervention for nocturia in men. J Am Geriatr Soc 2005; 53:S94.</a></li><li><a class="nounderline abstract_t">Papworth E, Dawson S, Henderson EJ, et al. Association of Sleep Disorders with Nocturia: A Systematic Review and Nominal Group Technique Consensus on Primary Care Assessment and Treatment. Eur Urol Focus 2022; 8:42.</a></li><li><a class="nounderline abstract_t">Dawson S, Duncan L, Ahmed A, et al. Assessment and Treatment of Nocturia in Endocrine Disease in a Primary Care Setting: Systematic Review and Nominal Group Technique Consensus. Eur Urol Focus 2022; 8:52.</a></li><li><a class="nounderline abstract_t">Choi B, Ehsan A, Nakhoul M, et al. The Impact of Bariatric Surgery on Nocturia Symptoms: a Systematic Review and Meta-Analysis. Obes Surg 2022; 32:3150.</a></li><li><a class="nounderline abstract_t">Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int 2008; 102:62.</a></li><li><a class="nounderline abstract_t">Yoshikawa M, Torimoto K, Hirayama A, et al. Daily salt intake is associated with leg edema and nocturnal urinary volume in elderly men. Neurourol Urodyn 2020; 39:1550.</a></li><li><a class="nounderline abstract_t">Matsuo T, Miyata Y, Sakai H. Effect of salt intake reduction on nocturia in patients with excessive salt intake. Neurourol Urodyn 2019; 38:927.</a></li><li><a class="nounderline abstract_t">Burgio KL. Current perspectives on management of urgency using bladder and behavioral training. J Am Acad Nurse Pract 2004; 16:4.</a></li><li><a class="nounderline abstract_t">Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 2002; 288:2293.</a></li><li><a class="nounderline abstract_t">Johnson TM 2nd, Burgio KL, Redden DT, et al. Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc 2005; 53:846.</a></li><li><a class="nounderline abstract_t">Burgio KL, Goode PS, Johnson TM, et al. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. J Am Geriatr Soc 2011; 59:2209.</a></li><li><a class="nounderline abstract_t">Johnson TM 2nd, Markland AD, Goode PS, et al. Efficacy of adding behavioural treatment or antimuscarinic drug therapy to α-blocker therapy in men with nocturia. BJU Int 2013; 112:100.</a></li><li><a class="nounderline abstract_t">Johnson TM 2nd, Vaughan CP, Goode PS, et al. Pilot Results from a Randomized Trial in Men Comparing Alpha-Adrenergic Antagonist versus Behavior and Exercise for Nocturia and Sleep. Clin Ther 2016.</a></li><li><a class="nounderline abstract_t">Burgio KL, Goode PS. Behavioral interventions for incontinence in ambulatory geriatric patients. Am J Med Sci 1997; 314:257.</a></li><li><a class="nounderline abstract_t">Tyagi S, Resnick NM, Perera S, et al. Behavioral treatment of insomnia: also effective for nocturia. J Am Geriatr Soc 2014; 62:54.</a></li><li><a class="nounderline abstract_t">Vaughan CP, Markland AD, Huang AJ, et al. Considerations for integrated cognitive behavioural treatment for older adults with coexisting nocturia and insomnia. Age Ageing 2022; 51.</a></li><li><a class="nounderline abstract_t">Johnson TM 2nd, Jones K, Williford WO, et al. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003; 170:145.</a></li><li><a class="nounderline abstract_t">McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387.</a></li><li><a class="nounderline abstract_t">Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335:533.</a></li><li><a class="nounderline abstract_t">de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998; 33:481.</a></li><li><a class="nounderline abstract_t">Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92:257.</a></li><li><a class="nounderline abstract_t">Ruggieri MR Sr, Braverman AS, Pontari MA. Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 2005; 174:1743.</a></li><li><a class="nounderline abstract_t">Johnson TM 2nd, Burrows PK, Kusek JW, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 2007; 178:2045.</a></li><li><a class="nounderline abstract_t">Meyhoff HH, Nordling J. Long term results of transurethral and transvesical prostatectomy. A randomized study. Scand J Urol Nephrol 1986; 20:27.</a></li><li><a class="nounderline abstract_t">Homma Y. Classification of nocturia in the adult and elderly patient: a review of clinical criteria and selected literature. BJU Int 2005; 96 Suppl 1:8.</a></li><li><a class="nounderline abstract_t">Weiss JP, Blaivas JG, Bliwise DL, et al. The evaluation and treatment of nocturia: a consensus statement. BJU Int 2011; 108:6.</a></li><li><a class="nounderline abstract_t">Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172:1919.</a></li><li><a class="nounderline abstract_t">Yokoyama O, Yamaguchi O, Kakizaki H, et al. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J Urol 2011; 186:170.</a></li><li><a class="nounderline abstract_t">Harris WN, Everaert K. Overactive Bladder as a Key Driver of Nocturia: The Argument Against. Eur Urol Focus 2022; 8:6.</a></li><li><a class="nounderline abstract_t">Drake MJ, Chapple C, Esen AA, et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol 2016; 70:136.</a></li><li><a class="nounderline abstract_t">Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175:999.</a></li><li><a class="nounderline abstract_t">Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49:700.</a></li><li class="breakAll">Webb J. Potassium and anticholinergic drug interaction: Old dogs – no new tricks: potassium and anticholinergic medications. British Columbia Drug and Poison Information Centre (BC DPIC). http://www.dpic.org/article/professional/potassium-and-anticholinergic-drug-interaction (Accessed on May 20, 2019).</li><li><a class="nounderline abstract_t">Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296:2319.</a></li><li><a class="nounderline abstract_t">Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006; 60:959.</a></li><li class="breakAll">BioSpace. Urovant Sciences announces US FDA approval of GEMTESA (vibegron) 75 mg tablets for the treatment of patients with overactive bladder (OAB). December 2020. Available at: https://www.biospace.com/article/releases/urovant-sciences-announces-u-s-fda-approval-of-gemtesa-vibegron-75-mg-tablets-for-the-treatment-of-patients-with-overactive-bladder-oab-/ (Accessed on January 10, 2021).</li><li><a class="nounderline abstract_t">Yoshida M, Takeda M, Gotoh M, et al. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int 2020; 125:709.</a></li><li><a class="nounderline abstract_t">Kelleher C, Hakimi Z, Zur R, et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol 2018; 74:324.</a></li><li><a class="nounderline abstract_t">Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013; 67:619.</a></li><li><a class="nounderline abstract_t">Yoshida M, Takeda M, Gotoh M, et al. Efficacy of novel β3 -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. Int J Urol 2019; 26:369.</a></li><li><a class="nounderline abstract_t">Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014; 124:1147.</a></li><li><a class="nounderline abstract_t">Everaert K, Hervé F, Bosch R, et al. International Continence Society consensus on the diagnosis and treatment of nocturia. Neurourol Urodyn 2019; 38:478.</a></li><li class="breakAll">Nocdurna [prescribing information]. Ferring Pharmaceuticals; 2018. (Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022517s000lbl.pdf (accessed October 22, 2018)).</li><li class="breakAll">Noctiva [prescribing information]. Serenity Pharmaceuticals; 2017. (Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201656lbl.pdf (accessed September 22, 2018)).</li><li class="breakAll">Blue Cross Blue Shield Federal Employee Program. Policy: Nocdurna Noctiva. 2020. Available at: https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/-/media/pdfs/medical%20policies/12_19_19/5_30_58%20nocdurna%20noctiva.pdf (Accessed on September 06, 2020).</li><li><a class="nounderline abstract_t">Fralick M, Schneeweiss S, Wallis CJD, et al. Desmopressin and the risk of hyponatremia: A population-based cohort study. PLoS Med 2019; 16:e1002930.</a></li><li><a class="nounderline abstract_t">Suvada K, Plantinga L, Vaughan CP, et al. Comorbidities, Age, and Polypharmacy Limit the Use by US Older Adults with Nocturia of the Only FDA-approved Drugs for the Symptom. Clin Ther 2020; 42:e259.</a></li><li><a class="nounderline abstract_t">Cvetković RS, Plosker GL. Desmopressin: in adults with nocturia. Drugs 2005; 65:99.</a></li><li class="breakAll">https://www.merckmanuals.com/professional/clinical-pharmacology/adverse-drug-reactions/adverse-drug-reactions (Accessed on May 30, 2019).</li><li><a class="nounderline abstract_t">Weiss JP, Zinner NR, Klein BM, Nørgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn 2012; 31:441.</a></li><li><a class="nounderline abstract_t">Juul KV, Klein BM, Sandström R, et al. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol 2011; 300:F1116.</a></li><li><a class="nounderline abstract_t">Rembratt A, Norgaard JP, Andersson KE. Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns. BJU Int 2003; 91:642.</a></li><li><a class="nounderline abstract_t">Ljung R. Use of desmopressin and concomitant use of potentially interacting drugs in elderly patients in Sweden. Eur J Clin Pharmacol 2008; 64:439.</a></li><li class="breakAll">DDAVP (desmopressin acetate) nasal spray. US FDA approved product information; Ferring
Pharmaceuticals Inc, September 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017922s046lbl.pdf (Accessed on January 10, 2021).</li><li><a class="nounderline abstract_t">Rembratt A, Graugaard-Jensen C, Senderovitz T, et al. Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol 2004; 60:397.</a></li><li><a class="nounderline abstract_t">Johnson TM, Burridge A, Issa MM, et al. The relationship between the action of arginine vasopressin and responsiveness to oral desmopressin in older men: a pilot study. J Am Geriatr Soc 2007; 55:562.</a></li><li><a class="nounderline abstract_t">Wang CJ, Lin YN, Huang SW, Chang CH. Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study. J Urol 2011; 185:219.</a></li><li><a class="nounderline abstract_t">Ebell MH, Radke T, Gardner J. A systematic review of the efficacy and safety of desmopressin for nocturia in adults. J Urol 2014; 192:829.</a></li><li><a class="nounderline abstract_t">Han J, Jung JH, Bakker CJ, et al. Desmopressin for treating nocturia in men. Cochrane Database Syst Rev 2017; 10:CD012059.</a></li><li><a class="nounderline abstract_t">Fralick M, Kesselheim AS. FDA Approval of Desmopressin for Nocturia. JAMA 2017; 317:2059.</a></li><li><a class="nounderline abstract_t">Hvistendahl GM, Riis A, Nørgaard JP, Djurhuus JC. The pharmacokinetics of 400 microg of oral desmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effect. BJU Int 2005; 95:804.</a></li><li><a class="nounderline abstract_t">Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurourol Urodyn 2004; 23:302.</a></li><li><a class="nounderline abstract_t">Juul KV, Malmberg A, van der Meulen E, et al. Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia. BJU Int 2017; 119:776.</a></li><li><a class="nounderline abstract_t">Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010; 183:1438.</a></li><li><a class="nounderline abstract_t">MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol 2010; 183:234.</a></li><li><a class="nounderline abstract_t">Sonmez R, Yildiz N, Alkan H. Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: A prospective randomised controlled trial. Ann Phys Rehabil Med 2022; 65:101486.</a></li><li><a class="nounderline abstract_t">Drake MJ, Mills IW, Noble JG. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol 2004; 171:1199.</a></li><li><a class="nounderline abstract_t">Pedersen PA, Johansen PB. Prophylactic treatment of adult nocturia with bumetanide. Br J Urol 1988; 62:145.</a></li><li><a class="nounderline abstract_t">Reynard JM, Cannon A, Yang Q, Abrams P. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol 1998; 81:215.</a></li><li><a class="nounderline abstract_t">Fu FG, Lavery HJ, Wu DL. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourol Urodyn 2011; 30:312.</a></li></ol></div><div id="topicVersionRevision">Topic 6877 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19937315" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19361907" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11371880" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Adult onset nocturnal enuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9726759" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Enuresis and obstructive sleep apnea in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30723807" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nocturnal enuresis as the initial symptom of life-threatening arrhythmia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35501108" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bedwetting from the heart: Time for a paradigm shift in the minimal diagnostic evaluation of enuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23234639" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The prevalence and causes of nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16407003" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Is nocturia equally common among men and women? A population based study in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21251675" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence of nocturia in United States men: results from the National Health and Nutrition Examination Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19233415" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Are racial/ethnic disparities in the prevalence of nocturia due to socioeconomic status? Results of the BACH survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20406317" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence and correlates of nocturia in community-dwelling older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25560101" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The burden of nocturia among middle-aged and older women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26516809" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bladder Symptoms and Attitudes in an Ethnically Diverse Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22197347" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Overactive bladder: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11835420" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The risk of lower urinary tract symptoms five years after the first delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18486094" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reproductive factors associated with nocturia and urinary urgency in women: a population-based study in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17445653" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Association between urogenital symptoms and depression in community-dwelling women aged 20 to 70 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382738" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15935026" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evaluating potentially modifiable risk factors for prevalent and incident nocturia in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19515794" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A systematic evaluation of factors associated with nocturia--the population-based FINNO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18353377" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28129482" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nocturia increases the incidence of depressive symptoms: a longitudinal study of the HEIJO-KYO cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23680309" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The association of depression, anxiety and nocturia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7692104" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. The Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16874440" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Perception of nocturia and medical consulting behavior among community-dwelling women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7544816" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Implications of the most bothersome prostatism symptom for clinical care and outcomes research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22299137" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The role of nocturia in the quality of life of men with lower urinary tract symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630703" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Subjective sleep characteristics of 1,485 males and females aged 50-93: effects of sex and age, and factors related to self-evaluated quality of sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22356249" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Self-rated sleep characteristics and bother from nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180617" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nocturia and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456212" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The association of nocturia with incident falls in an elderly community-dwelling cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1447437" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Nocturia: a risk factor for falls in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22763143" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Association between nocturia and falls-related long-term mortality risk in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19301408" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nocturia is an age-independent risk factor for hip-fractures in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20727545" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10604303" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25881866" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nocturia: Current Levels of Evidence and Recommendations From the International Consultation on Male Lower Urinary Tract Symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180618" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The 24-h frequency-volume chart in adults reporting no voiding complaints: defining reference values and analysing variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16551306" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The effect of age on lower urinary tract function: a study in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10529704" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evaluation of the etiology of nocturia in men: the nocturia and nocturnal bladder capacity indices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11857672" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1171896" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Diurnal variation of plasma vasopressin in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1997638" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Diurnal variation in the levels of antidiuretic hormone in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8808857" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11037022" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Nocturnal polyuria in older people: pathophysiology and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6416541" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Patterns of urine flow and electrolyte excretion in healthy elderly people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26687922" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Evaluation of Polyuria: The Roles of Solute Loading and Water Diuresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703381" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Nocturia and disturbed sleep in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12627734" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prevalence and predictors of nocturia in obstructive sleep apnea-hypopnea syndrome--a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18400277" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Nocturia in men less than 50 years of age may be associated with obstructive sleep apnea syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18455544" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The relationship between obstructive sleep apnea, nocturia, and daytime overactive bladder syndrome in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16579944" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Nocturic frequency is related to severity of obstructive sleep apnea, improves with continuous positive airways treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16635510" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Continuous positive airway pressure reduces nocturia in patients with obstructive sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14998251" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Obstructive sleep apnea, nocturia and polyuria in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2530023" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Atrial natriuretic peptide release during sleep in patients with obstructive sleep apnoea before and during treatment with nasal continuous positive airway pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26620900" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The Efficacy of Continuous Positive Airway Pressure Therapy on Nocturia in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8604961" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Nocturia. A rarely recognized symptom of sleep apnea and other occult sleep disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7267962" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Circadian variations in urine excretion in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26075489" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Diagnostic Accuracy of Tests for Polyuria in Lithium-Treated Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14709263" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treating urinary incontinence in the elderly--conservative therapies that work: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17096320" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28295650" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Daily salt intake is an independent risk factor for pollakiuria and nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32049435" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sodium restriction improves nocturia in patients at a cardiology clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27105762" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sleep Apnea and Circadian Extracellular Fluid Change as Independent Factors for Nocturnal Polyuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35101453" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Evaluation and Treatment in Urology for Nocturia Caused by Nonurological Mechanisms: Guidance from the PLANET Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19865841" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Nocturia and snoring: predictive symptoms for obstructive sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21316091" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Relationship between nocturnal urine volume, leg edema, and urinary antidiuretic hormone in older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8908664" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Frequency volume charts: an indispensable part of lower urinary tract assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16458734" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Nocturia: "do the math".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35094963" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The Importance of Terminology for Quantifying Nocturia in Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16280803" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16280803" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21661016" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Nocturia: new directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21661016" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Nocturia: new directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20643422" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy of nondrug lifestyle measures for the treatment of nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A multicomponent intervention for nocturia in men</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35027331" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Association of Sleep Disorders with Nocturia: A Systematic Review and Nominal Group Technique Consensus on Primary Care Assessment and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34996740" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Assessment and Treatment of Nocturia in Endocrine Disease in a Primary Care Setting: Systematic Review and Nominal Group Technique Consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35864289" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The Impact of Bariatric Surgery on Nocturia Symptoms: a Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284414" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : How should patients with an overactive bladder manipulate their fluid intake?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32460398" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Daily salt intake is associated with leg edema and nocturnal urinary volume in elderly men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30706965" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effect of salt intake reduction on nocturia in patients with excessive salt intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15543926" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Current perspectives on management of urgency using bladder and behavioral training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12425706" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15877562" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effects of behavioral and drug therapy on nocturia in older incontinent women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22092152" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23448285" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Efficacy of adding behavioural treatment or antimuscarinic drug therapy toα-blocker therapy in men with nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28029383" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pilot Results from a Randomized Trial in Men Comparing Alpha-Adrenergic Antagonist versus Behavior and Exercise for Nocturia and Sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9332265" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Behavioral interventions for incontinence in ambulatory geriatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24383406" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Behavioral treatment of insomnia: also effective for nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35165690" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Considerations for integrated cognitive behavioural treatment for older adults with coexisting nocturia and insomnia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796667" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14681504" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8684407" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9643668" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12887479" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16217275" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17869295" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2422742" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Long term results of transurethral and transvesical prostatectomy. A randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16083451" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Classification of nocturia in the adult and elderly patient: a review of clinical criteria and selected literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21676145" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The evaluation and treatment of nocturia: a consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15540755" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21575976" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35027328" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Overactive Bladder as a Key Driver of Nocturia: The Argument Against.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26965560" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16469601" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454106" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Tolterodine: a safe and effective treatment for older patients with overactive bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454106" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Tolterodine: a safe and effective treatment for older patients with overactive bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17105794" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16893438" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Solifenacin significantly improves all symptoms of overactive bladder syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16893438" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Solifenacin significantly improves all symptoms of overactive bladder syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31991511" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Efficacy of vibegron, a novelβ3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29699858" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23692526" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30557916" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Efficacy of novelβ3 -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25415166" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Vaginal estrogen for genitourinary syndrome of menopause: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779378" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : International Continence Society consensus on the diagnosis and treatment of nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779378" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : International Continence Society consensus on the diagnosis and treatment of nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779378" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : International Continence Society consensus on the diagnosis and treatment of nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779378" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : International Continence Society consensus on the diagnosis and treatment of nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31634354" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Desmopressin and the risk of hyponatremia: A population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33257091" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Comorbidities, Age, and Polypharmacy Limit the Use by US Older Adults with Nocturia of the Only FDA-approved Drugs for the Symptom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15610055" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Desmopressin: in adults with nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15610055" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Desmopressin: in adults with nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22447415" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367921" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Gender difference in antidiuretic response to desmopressin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12699476" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180913" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Use of desmopressin and concomitant use of potentially interacting drugs in elderly patients in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180913" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Use of desmopressin and concomitant use of potentially interacting drugs in elderly patients in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15197520" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17397435" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : The relationship between the action of arginine vasopressin and responsiveness to oral desmopressin in older men: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21074790" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24704009" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : A systematic review of the efficacy and safety of desmopressin for nocturia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29055129" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Desmopressin for treating nocturia in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28384655" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : FDA Approval of Desmopressin for Nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15794787" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : The pharmacokinetics of 400 microg of oral desmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15227644" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27862898" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171677" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19913821" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33429090" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: A prospective randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767300" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2457403" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Prophylactic treatment of adult nocturia with bumetanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9488061" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21305590" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
